Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International)

Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals. The agreement is worth in excess of $200 million in up-front and milestone payments. (BioWorld International)

Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals. The agreement is worth in excess of $200 million in up-front and milestone payments. (BioWorld International)

Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals Inc., which is worth well in excess of $200 million in up-front fees and milestone payments. (BioWorld Today)

Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals Inc., which is worth well in excess of $200 million in up-front fees and milestone payments. (BioWorld Today)